Non-Invasive Liver Tests (NITs) - A Guide for Australian Clinicians
The modern liver pathway is no longer biopsy first. Non-invasive liver tests now act as a layered decision system, helping clinicians decide who can be reassured, who needs elastography, and who needs specialist escalation.
Content note
Prepared by the Elastography Australia clinical education team for informational purposes. This content does not replace clinician judgement or individual medical advice.
The three broad NIT categories
Non-invasive liver tests usually fall into blood-based scores, elastography-based tests, and wider imaging biomarkers. Each category answers a slightly different clinical question and comes with different access and workflow implications.
- Blood-based scores: FIB-4, APRI, ELF and related formulas.
- Elastography: transient elastography, shear wave elastography, and MRI elastography.
- Imaging biomarkers: morphology on ultrasound and more advanced radiology signals.
Why elastography sits in the middle of the pathway
Blood tests are accessible but indirect. Biopsy is direct but invasive. Elastography occupies the high-value middle ground because it is more specific than a score and far more scalable than biopsy.
That is why the playbook repeatedly positions elastography as the preferred second-line test after indeterminate first-line screening results.
The Australian access question
The barrier in Australia is not awareness of NITs but where they are available and how easily clinicians can move from first-line screening to second-line confirmation.
A device like Elastography Australia is therefore positioned as infrastructure for a better pathway, not just as another imaging purchase.
How to use NITs practically
Use low-cost tests such as FIB-4 to sort risk early, use elastography to refine staging and triage indeterminate cases, and reserve biopsy or advanced imaging for situations where the answer will change management substantially.